Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: AI
The US Food and Drug Administration has expanded the recall of frozen blueberries and berry blends after an outbreak of E. coli O145 linked to frozen organic blueberries sickened 17 people in two states.
The latest recall does not mean that the outbreak is growing. The CDC recently declared that the outbreak was over on September 21, with no new illnesses reported since then. But on October 2, the company at the centre of the investigation expanded its recall to include additional batches of frozen berry products after the FDA obtained new information during an onsite inspection.
The agency said the company had previously not provided all records requested by FDA investigators. After obtaining additional information, the FDA identified more products that could be contaminated and the company expanded its recall.
The FDA has also added the Chilean company, Frutas y Hortalizas del Sur S.A.. to Import Alert 99-35, which means that frozen blueberries from the company entering the US can be detained without physical examination.
The expanded recall involves products sold under Great Value and Trader Joe’s brands. The affected products include:
The recalled Great Value products were distributed to Walmart stores in 30 states and Puerto Rico, while the recalled Trader Joe’s berry blend was distributed more widely through the retailer. Consumers who have the affected products should not eat them and should discard them or return them for a refund.
Some of the recalled products have 'Best By' dates extending into 2028, meaning they could still be sitting in consumers' freezers despite the outbreak having ended.
According to the CDC and FDA, 17 people were infected due to E. coli outbreak across Florida and Georgia. There were six hospitalisations and zero fatalities.
Infections were reported between May 11 and August 2, 2026. Among 13 people interviewed during the investigation, 11 reported eating frozen blueberries, which strengthened the epidemiological link to the packaged produce.
Earlier in the investigation, one sample of GreenWise frozen organic blueberries collected by Publix tested positive for the same E. coli strain responsible for the illnesses. This led to recalls that were subsequently expanded to other products from the same supplier.
E. coli O145 belongs to a group known as Shiga toxin-producing E. coli (STEC). These bacteria can cause severe stomach cramps, diarrhoea, vomiting and, in some cases, bloody diarrhoea.
Most people recover, but the infection can sometimes lead to haemolytic uremic syndrome (HUS), a serious complication that can cause kidney failure. Young children, older adults and people with weak and strained immunity are particularly vulnerable to severe illness.
People who develop symptoms after eating a recalled product should contact a healthcare provider, particularly if they develop bloody diarrhoea, severe abdominal pain or signs of dehydration.
Consumers should also check their freezers rather than assume recalled products have already been removed from stores. The FDA says recalled products should no longer be available for sale, but some have long shelf lives and may still be at home.
Anyone with one of the affected lot codes should not taste the product to determine whether it is safe. It should be discarded or returned for a refund.
Credit: AI
Russia has told the World Health Organization (WHO) that no cases of plague have been recorded in Irkutsk, the Siberian city that has sparked international headlines after a laboratory worker from an anti-plague research institute died after suspected exposure to pneumonic plague infection.
The WHO said Russian authorities responded on October 6 to its request for information under the International Health Regulations (IHR), saying the woman’s illness had initially appeared to be a typical acute respiratory viral infection.
Russia also reported that no plague case had been recorded in Irkutsk, either in the woman or among her contacts.
However, the exact cause of the woman’s death still remains unclear.
The WHO recently said, “WHO is aware of media reports that a laboratory worker in Irkutsk oblast, in the Russian Federation, died of suspected pneumonic plague, and that nearly 200 of her contacts were under medical observation and being tested."
“On 3 October, WHO asked the Russian authorities under the International Health Regulations (IHR) for any further information they had, so we could assess the risk.”
The WHO said Russia reported that “no case of plague has been recorded in Irkutsk, either in her or in anyone else.”
Adding further, the health body said, "They informed WHO that an epidemiological investigation had been conducted, preventive and control measures implemented, and identified contacts placed under medical observation and tested. They reported that no high-threat pathogens had been detected among the contacts and that medical observation of all identified contacts had been completed."
But the agency is still seeking an answer on what caused the fatal pneumonia as the lab worker's death still remains a mystery.
It said, “WHO has remained in contact with the Russian health authorities and has offered technical support. WHO has requested further information to clarify the cause of the severe pneumonia, the pathogen that prompted the public health measures, and media reports of a second employee with pneumonia of undetermined cause.”
Also read: Russia Plague Scare: What Black Death and Anthrax Outbreaks Teach Us About Lab Safety
The 28-year-old woman, identified by Russian media as Darya Shipilova, worked at the Irkutsk Anti-Plague Research Institute of Siberia and the Far East. She died on October 2 after developing severe pneumonia of "unknown origin", according to Russian authorities.
Her death sparked precautionary measures including quarantine. According to reports, around 200 people who had contact with her placed under medical observation. Russian health authorities said testing of those contacts found no dangerous infectious-disease pathogens. Some contacts reportedly tested positive for COVID-19 or rhinovirus.
Reports circulating on social media claimed she may have been infected after a laboratory accident involving Yersinia pestis, the bacterium that causes plague. Russian authorities have rejected the laboratory-accident theory, and there is currently no independent evidence confirming that such an incident occurred.
Also read: Russia Plague Scare: Is Pneumonic Plague Deadlier Than Bubonic & Septicemic Plague?
Javier Pizarro-Cerda, head of the Yersinia Research Unit at the Institut Pasteur in Paris, told CNBC that he was “very surprised” by the reported death because laboratories handling plague generally use strict protective measures.
“You work with a full body suit. You work with masks. You work with gloves. So even if you break a tube, normally you should be protected,” he said.
Pizarro-Cerda also said Russia has a plague vaccine, although he described its protection as low and transient compared with standards elsewhere.
Pizarro-Cerda said plague testing can be performed rapidly and that an autopsy should provide evidence if the woman had pulmonary plague.
The laboratory worker reportedly died on October 2, giving authorities several days to conduct diagnostic tests. Still, there is no confirmation that pneumonic plague caused her death or that a laboratory accident occurred.
Key questions remain whether Yersinia pestis was detected, whether there was evidence of laboratory exposure, and whether genetic testing can establish the source of any infection.
The suspected plague is still being investigated. The concern stems partly from the nature of the institute where Shipilova worked. The facility studies dangerous pathogens, including plague, in a region where the disease occurs naturally among wild animals.
Pneumonic plague is the most severe form of plague because it affects the lungs and can spread between people through respiratory droplets. Plague is treatable with antibiotics when diagnosed and treated promptly.
The WHO has assessed the public-health risk as moderate-to-low for Irkutsk, low for Russia overall and very low for the WHO European region.
Credit: AI
Aspirin has long been studied for its role in colorectal cancer prevention. But a new trial suggests that when aspirin is started may be of more importance compared to whether it is used at all.
In the latest study, researchers discovered that aspirin did not prevent cancer recurrence or improve survival in people whose colorectal cancer had already spread to the liver.
The study, published in The Lancet Gastroenterology & Hepatology, is based on 428 patients who were treated for colorectal cancer liver metastases at 14 hospitals across Norway, Sweden and Denmark. Participants were randomly assigned to receive either 160 mg of aspirin or a placebo every day for up to three years.
After treatment for their liver metastases, patients taking aspirin did not have better results than others who took placebo.
In fact, after three years, 76% of people in the aspirin group were alive compared to 85% in the placebo group. Researchers say that the overall survival was a secondary outcome. They also said that the trial was not designed to provide a definitive answer about that measure.
Serious adverse events were also more common with aspirin, occurring in 8% of the aspirin group compared with 2% of the placebo group. Reported complications included heart attacks, nosebleeds, duodenal ulcers and cerebral haemorrhage.
“Although aspirin has been shown to reduce recurrence rates in patients who have undergone surgery for a primary tumour in the colon or rectum, its effects still need to be evaluated in the specific patient group for which it is intended, in this case patients with colorectal cancer that has spread to the liver. We found no clear benefit in this group, while serious adverse events were more common,” said Ernesto Sparrelid, adjunct professor at Karolinska Institutet.
The new findings contrast with results from the ALASCCA trial, which found that low-dose aspirin reduced colorectal cancer recurrence in patients whose tumours had alterations in genes related to PI3K.
In that trial, the three-year recurrence rate was 7.7% with aspirin versus 14.1% with placebo among patients with specific PIK3CA alterations.
This suggests that aspirin may not be a universal anti-cancer drug. Its benefit may largely depend on the biology of the tumour and how advanced the cancer stage is.
“The anticancer effects of aspirin may depend on the biological and clinical context,” said co-principal investigator Kjetil Taskén of the University of Oslo.
Another possible explanation is that aspirin's anti-inflammatory and anti-platelet effects may interfere with some of the biological processes involved in early tumour growth and recurrence. But once cancer has already spread, particularly to the liver, the biology becomes more complex.
“Aspirin is a well-established, inexpensive and widely available drug, and there is considerable interest in whether it can also reduce the risk of cancer recurrence,” said lead author Sheraz Yaqub of the University of Oslo. “Our findings demonstrate why such treatments must be tested in rigorous randomized trials before being adopted for new patient populations.”
Also read: Trump Says He ‘Psychologically’ Needs To Pop Aspirin Every Day: But Is It Actually Safe?
The findings come just days after President Donald Trump disclosed that he takes aspirin every day, adding that prefers a full-strength tablet.
At an October 3 rally in Ohio, Trump said, “I take an aspirin a day. I don't know if it works, but psychologically I need it.” He also said doctors had wanted him to switch to a lower dose, but that he preferred the larger tablet.
Trump's comments have reignited discussion about daily aspirin use, but they should not be interpreted as medical advice.
Aspirin may reduce clot formation, but it can also increase the risk of serious bleeding. The American Heart Association says routine daily aspirin is generally not recommended for healthy adults without cardiovascular disease unless advised by a healthcare professional.
And the new cancer findings add another reason not to assume that taking aspirin routinely will prevent cancer or improve outcomes after a diagnosis.
© $2026 Times Horizon Private Limited